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dard treatment, including ASA, in patients with acute
coronary syndromes without ST-elevation.
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OBJECTIVES: To analyse the efﬁciency of the use of a
percutaneous transluminal coronary angioplasty (PTCA),
a coronary artery bypass graft (CABG), a conventional
Stent or a sirolimus-eluting Stent (Cypher) in the treat-
ment of Ischaemic Heart Disease (IHD) by means of a
cost-effectiveness analysis. METHODS: An international
decision analytical model was adapted to the Spanish
National Health System perspective in a time horizon of
1 year for 4 different populations of general patients with
IHD according to the type of vessel or lesion (one or 
multiple, small vessel—less that 3mm diameter, or long
lesion—more than 18mm long). The primary outcome of
the model was the cost per revascularisation avoided with
each technique when compared to a conventional Stent
(in the multiple lesions model the PTCA has not been 
considered as a relevant option). Incidence rates of re-
vacularisation for each subgroup were obtained from
published clinical trials and epidemiological studies.
Resource use data was determined by an expert panel.
Unit costs of the resources were extracted from local data-
bases and were expressed in Euros of 2002. RESULTS:
The PTCA has the lowest efﬁcacy with revascularisation
rates ranging from 19% to 28%) whilst the sirolimus
eluting-Stent is the most efﬁcacious option (rates ranging
from 1% to 4%. The less costly option is PTCA and the
most expensive in all types of patients is the CABG. Cost
per revascularisation avoided ranges between €1,042 of a
PTCA in small vessel patients to €56,035 with CABG in
patients with lesions in normal vessels. Cypher is a cost-
effective option in patients with normal vessels and long
lesions and becomes dominant in the multiple lesions
model. CONCLUSIONS: Drug eluting Stents have
proven efﬁcacy rates that have no precedents in the
history of IHD, reducing the incidence of revascularisa-
tion induced by restenosis and thus resulting in efﬁcient
options in most types of patients.
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OBJECTIVES: To quantify the economic value of the
sirolimus-eluting stent (SES) in treating acute coronary
heart disease, and to assist in determining its adequate
reimbursement price under the mandatory national health
insurance system in Korea. METHODS: A decision-
analytic model was used to investigate the incremental
cost-effectiveness of SES versus conventional stenting
(CS). Probabilities for clinical events were obtained from
the results of large, randomized, controlled clinical trials.
Types of costs included in the analysis were initial proce-
dure and hospitalization costs, and follow-up direct
medical costs for 5 years consisting of routine follow-up
treatments, adverse reactions, revascularization and death
costs. Cost information was obtained from administrative
data for 449 patients receiving CS in June 2002 from 5
Korean hospitals participating in this study. Since the
major clinical advantage of SES over CS is the reduction
of revascularization rates, we evaluated economic value
of SES in relation to direct medical costs of revascular-
ization. According to the customary notion in Korea, the
reimbursement price was deﬁned as the price of SES that
made the incremental cost-effectiveness ratio equal to the
cost of a revascularization itself. RESULTS: The esti-
mated reimbursement price for SES was US$3344 using
a discount rate of 5%. Based on this price, the national
ﬁnancial impact of replacing CS with SES by 10% was
estimated as extra spending of $0.96 million a year, 0.6%
increase in total national spending in treating coronary
artery disease in Korea. CONCLUSIONS: Analysis on 
the economic value of SES based on Korean cost struc-
ture of coronary artery disease provided objective stan-
dard for pricing decision and reimbursement strategy in
Korea.
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OBJECTIVE: A recently published analysis on the use 
of Cholesterol-Synthesis-Enzyme-Antagonists (CSEA) in
Germany stated that with the investment of nearly €1
billion; 87% of all possible €2.8 million. patients can be
treated sufﬁciently (Klose and Schwabe 2003). The aim
of the presented study is to show the cost-efﬁcacy as expe-
rienced by ofﬁce based physicians of the CSEA treatment.
METHODS: A cost-efﬁcacy-analysis was conducted on
base of the following data: Eight local experts (general
practitioners, cardiologists) out of a rural as well as an
urban setting assessed in a Delphi-Panel their practical
experience of reaching a deﬁned LDL-Cholesterol (LDL-
C) target according to European treatment guidelines
treating a patient with a predeﬁned risk with CSEA. Total
sales of CSEA in 2002 as stated by IMS (Institute for
